Ventyx Biosciences Q3 net loss narrows to $22.8 mln

Ventyx Biosciences

06/11/2025 21:33

Overview

Ventyx Q3 net loss narrows to $22.8 mln from $35.2 mln last year

Company's cash reserves expected to fund operations into at least H2 2026

VTX3232 shows promising Phase 2 results for cardiovascular and Parkinson's disease

Outlook

Company expects topline data from VTX2735 study in Q4 2025

Ventyx's cash expected to fund operations into at least H2 2026

Result Drivers

FINANCIAL POSITION - Cash reserves of $192.6 mln expected to fund operations into at least H2 2026

Expenses - R&D expenses fell to $17.7 mln from $30.6 mln a year ago, while general and administrative costs declined to $7.2 mln from $7.9 mln

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.32
Q3 Net Income
-$22.83 mln
Q3 Operating Expenses
$24.87 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Ventyx Biosciences Inc is $12.00, about 25% above its November 5 closing price of $9.00

Press Release: ID:nGNX1WBR9C

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)